Steven Fischkoff

7.2k citations

47 papers · 5.7k indexed · 3 hit papers · h-index 27

Rheumatology top 0.1%
Immunology top 1%
Hematology top 0.5%
Molecular Biology top 10%
Genetics top 1%

Co-authors: Elliot Chartash Edward Keystone Daniel E. Furst C. Birbara Michael H. Weisman Larry W. Moreland Michael E. Weinblatt Leah Teoh
Topics: Eosinophilic Disorders and Syndromes (6 papers)Lipid Membrane Structure and Behavior (6 papers)Lymphoma Diagnosis and Treatment (6 papers)
Cited by: Rheumatology Hematology Genetics
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry The Journal of Chemical Physics
Partner nations: United States Canada United Kingdom

In The Last Decade

Steven Fischkoff

47 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial

2003 1.4k citations Michael E. Weinblatt, Edward Keystone et al. Arthritis & Rheumatism profile →
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

2004 956 citations Edward Keystone, Arthur F. Kavanaugh et al. Arthritis & Rheumatism profile →
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

2004 512 citations L.B.A. van de Putte, Catherine Atkin et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Steven Fischkoff

Since Specialization

Citations

This map shows the geographic impact of Steven Fischkoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Fischkoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Fischkoff more than expected).

Fields of papers citing papers by Steven Fischkoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Fischkoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Fischkoff. The network helps show where Steven Fischkoff may publish in the future.

Co-authorship network of co-authors of Steven Fischkoff

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Fischkoff. A scholar is included among the top collaborators of Steven Fischkoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Fischkoff. Steven Fischkoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	137P Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors 2021 ·Annals of Oncology ·Gary Richardson,(unknown),Francis Parnis,(unknown),Anis Hamid,Kevin She,(unknown),Shuier Zheng,(unknown),(unknown),(unknown),X. Wang,(unknown),Steven Fischkoff,Hui Gong,Peter Luo	1
2	Human Placenta-derived Cells (PDA-001) for the Treatment of Moderate-to-severe Crohnʼs Disease 2015 ·Inflammatory Bowel Diseases ·Gil Melmed,William M. Pandak,Kevin Casey,Bincy Abraham,John F. Valentine,David A. Schwartz,(unknown),(unknown),Simon Lichtiger,Bruce E. Sands,Stephen B. Hanauer,Robert Richards,Ioannis Oikonomou,Nimisha Parekh,Stephen R. Targan,Kristine Johnson,Robert Hariri,Steven Fischkoff	52
3	Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. 2015 ·PubMed ·Robert P. Baughman,Daniel A. Culver,(unknown),Steven Fischkoff,(unknown),Elyse E. Lower	19
4	Safety and Tolerability of Human Placenta-Derived Cells (PDA001) in Treatment-Resistant Crohn’s Disease 2013 ·Inflammatory Bowel Diseases ·Lloyd Mayer,William M. Pandak,Gil Melmed,Stephen B. Hanauer,Kristine Johnson,(unknown),Herbert Faleck,Robert Hariri,Steven Fischkoff	57
5	1177: Phase IIB Study of Bremelanotide in the Treatment of ED in Diabetic Males 2007 ·The Journal of Urology ·Christopher P. Steidle,Norman R. Zinner,Gary Karlin,(unknown),Steven Fischkoff	3
6	Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* 2004 ·Critical Care Medicine ·Edward A. Panacek,John C. Marshall,Timothy E. Albertson,David H. Johnson,Steven B. Johnson,Rodger D. MacArthur,Mark Miller,William Barchuk,Steven Fischkoff,Martin Kaul,Leah Teoh,(unknown),(unknown),Stanley Lemeshow,(unknown),Christopher J. Doig	267
7	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedbreakdown → 2004 ·Annals of the Rheumatic Diseases ·L.B.A. van de Putte,Catherine Atkin,Michel Malaise,J Sany,Anthony S. Russell,(unknown),Loukas Settas,J. W. J. Bijlsma,S Todesco,Maxime Dougados,Peter Nash,Paul Emery,Nike Walter,Martin Kaul,Steven Fischkoff,H. Küpper	512
8	Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trialbreakdown → 2004 ·Arthritis & Rheumatism ·Edward Keystone,Arthur F. Kavanaugh,John T. Sharp,H Tannenbaum,Hua Ye,Leah Teoh,Steven Fischkoff,Elliot Chartash	956
9	Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study 2003 ·Clinical Therapeutics ·Michael H. Weisman,Larry W. Moreland,Daniel E. Furst,Michael E. Weinblatt,Edward Keystone,Harold E. Paulus,Leah Teoh,Raja Velagapudi,Peter Noertersheuser,G. Richard Granneman,Steven Fischkoff,Elliot Chartash	224
10	Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialbreakdown → 2003 ·Arthritis & Rheumatism ·Michael E. Weinblatt,Edward Keystone,Daniel E. Furst,Larry W. Moreland,Michael H. Weisman,C. Birbara,(unknown),Steven Fischkoff,Elliot Chartash	1413
11	A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome 2001 ·Intensive Care Medicine ·James J. Gallagher,Charles J. Fisher,Bruce W. Sherman,Mark Munger,Brandon M. Meyers,(unknown),Steven Fischkoff,William Barchuk,Leah Teoh,Raja Velagapudi	35
12	Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. 1998 ·Journal of Clinical Oncology ·Miguel A. Villalona‐Calero,Sharyn D. Baker,L. A. Hammond,(unknown),S. Gail Eckhardt,Maura A. Kraynak,Robert J. Fram,Steven Fischkoff,Raja Velagapudi,Deborah Toppmeyer,(unknown),(unknown),Daniel D. Von Hoff,Eric K. Rowinsky	24
13	Leukocyte chemotactic activity of cyclophilin. 1992 ·Journal of Biological Chemistry ·Qing Xu,María C. Leiva,Steven Fischkoff,Robert E. Handschumacher,C. Richard Lyttle	167
14	Eosinophil differentiation of human umbilical cord mononuclear cells and prolonged survival of mature eosinophils by murine EL-4 thymoma cell conditioned medium 1991 ·Cytokine ·Rosa Ten,(unknown),Hirohito Kita,Deborah A. Weiler,Steven Fischkoff,Teruko Ishizaka,Colin J. Sanderson,(unknown)	12
15	Glucocorticoid and Progestin Regulation of Eosinophil Chemotactic Factor and Complement C3 in the Estrogen Treated Rat Uterus* 1990 ·Endocrinology ·(unknown),(unknown),Steven Fischkoff,Cory Teuscher,C. Richard Lyttle	26
16	Characterization of interleukin 5 receptors on eosinophilic sublines from human promyelocytic leukemia (HL-60) cells. 1990 ·The Journal of Experimental Medicine ·Geert Plaetinck,José Van der Heyden,Jan Tavernier,(unknown),T Tuypens,Steven Fischkoff,Walter Fiers,René Devos	76
17	Lineage directed HL-60 cell sublines as a model system for the study of early events in lineage determination of myeloid cells 1990 ·Leukemia Research ·Steven Fischkoff,Randall M. Rossi	12
18	Graded increase in probability of eosinophilic differentiation of HL-60 promyelocytic leukemia cells induced by culture under alkaline conditions 1988 ·Leukemia Research ·Steven Fischkoff	69
19	Induction of differentiation of the human leukemia cell line, KU812 1987 ·Leukemia Research ·Steven Fischkoff,Kenji Kishi,W R Benjamin,Randall M. Rossi,(unknown),James A. Hoxie,C Seals,Linda A. Anderson,Teruko Ishizaka,J Hakimi	14
20	Oxygen diffusion in biological and artificial membranes determined by the fluorochrome pyrene. 1975 ·The Journal of General Physiology ·Steven Fischkoff,Jane M. Vanderkooi	182

About Steven Fischkoff

Steven Fischkoff is a scholar working on Genetics, Rheumatology and Hematology, having authored 47 papers that have together received 5.7k indexed citations. Recurring topics across this work include Eosinophilic Disorders and Syndromes (6 papers), Lipid Membrane Structure and Behavior (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Rheumatology (2.9k citations), Hematology (1.5k citations) and Genetics (828 citations). Steven Fischkoff has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Elliot Chartash, Edward Keystone, Daniel E. Furst, C. Birbara, Michael H. Weisman, Larry W. Moreland, Michael E. Weinblatt, Leah Teoh, Jane M. Vanderkooi and John T. Sharp. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Chemical Physics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact